Shionogi
As of the edition of 20 October 2026, Shionogi runs 56 drugs, 35 of them marketed; it is on route A at 3 targets and on route B at 18 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 35 |
| Active | 6 |
| Went quiet | 9 |
| Stopped | 2 |
| Status not established | 4 |
| Total | 56 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Cyclophosphamide anhydrous | none listed | 0 |
| Amoxicillin | none listed | 0 |
| Prednisolone | none listed | 6 |
| Ifosfamide | none listed | 0 |
| Duloxetine | none listed | 2 |
| Oxycodone | none listed | 2 |
| Metronidazole | none listed | 0 |
| Clarithromycin | none listed | 0 |
| Vancomycin | none listed | 0 |
| Tramadol | none listed | 3 |
| Glycopyrronium | none listed | 10 |
| Pirfenidone | none listed | 0 |
| Trimethoprim | none listed | 0 |
| Sulfamethoxazole | none listed | 0 |
| Lisdexamfetamine | none listed | 6 |
| Irbesartan | none listed | 2 |
| Guanfacine | none listed | 12 |
| Betamethasone | none listed | 6 |
| Edaravone | Ends 2029 (exclusivity) | 0 |
| Metreleptin | Ended 2026 (computed from the first US licence) | 0 |
| Doripenem | none listed | 0 |
| Cefiderocol | Ends 2035 (patent) | 0 |
| Baloxavir marboxil | Ends 2037 (patent) | 0 |
| Zuranolone | Ends 2037 (patent) | 0 |
| Peramivir anhydrous | none listed | 0 |
A route B row is one company at one target. 10 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 3 targets, route B at 18 targets.
All 21 rows on route A or B
In the product21 company-target rows on route A or B; 18 are not shown here, and no score is.
See all 21 targets where Shionogi needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Infections: 17 trials led
- Nutrition and metabolism: 16 trials led
- Lungs and airways: 15 trials led